Talquetamab

立即咨询

Talquetamab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

2226212-40-2

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议
10mg	电议
50mg	电议
100mg	电议

产品名称

JNJ-64407564

产品介绍

Talquetamab（JNJ-64407564）是一种人源化的双特异性抗体，可与GPRC5D(G 蛋白偶联受体家族C5组成员 D) 和CD3结合，通过T 细胞的募集和活化诱导 T 细胞介导的杀死表达 GPRC5 的 MM 细胞。Talquetamab（JNJ-64407564）具有抗肿瘤活性。

生物活性

Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds toGPRC5D(member of G protein-coupled receptor family C5 group D) andCD3to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity^[1]^[2].

体外研究
(In Vitro)

Talquetamab (0.00128-4.0 μg/mL, 48 h) 有效诱导多发性骨髓瘤细胞裂解，并导致活化的 CD⁴⁺和CD⁸⁺T 细胞比例显著增加，以及颗粒酶 B 和炎症细胞因子如 IL-6、IL-8 和 TNF-α 水平的剂量依赖性增加^[1].

体内研究
(In Vivo)

Talquetamab (JNJ-64407564) (0.1-50 μg, s.c. or i.v.)在 H929 和 MM 小鼠模型中有明显的抗肿瘤活性^[2]。

Animal Model:	Female NSG mice with H929 cells^[2]
Dosage:	0.1-10 μg (0.005 mg/kg)
Administration:	Subcutaneous injection; on days 0, 3, 5, 7, and 10
Result:	Completely blocked tumor formation at 1 μg and 10 μg doses.

Animal Model:	Female NSG mice with human MM cells^[2]
Dosage:	0.1-50 μg (0.005 mg/kg)
Administration:	Intravenous injection; on days 15, 18, 22, 24, 29, 32, and 36
Result:	Significantly inhibited tumor growth by 65% at the dose of 1μg and showed significant anti-tumor activity at 10 and 50 μg with complete tumor regression.

性状

Liquid

CAS 号

2226212-40-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.